Tlwm Has $1.09 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Tlwm boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,681 shares of the company’s stock after acquiring an additional 717 shares during the quarter. Tlwm’s holdings in AstraZeneca were worth $1,093,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Wallace Advisory Group LLC bought a new stake in AstraZeneca during the 4th quarter worth approximately $171,000. Tealwood Asset Management Inc. boosted its stake in AstraZeneca by 0.8% in the fourth quarter. Tealwood Asset Management Inc. now owns 37,410 shares of the company’s stock worth $2,451,000 after purchasing an additional 290 shares in the last quarter. Miracle Mile Advisors LLC grew its holdings in shares of AstraZeneca by 445.7% during the fourth quarter. Miracle Mile Advisors LLC now owns 39,986 shares of the company’s stock worth $2,620,000 after purchasing an additional 32,659 shares during the last quarter. Sivia Capital Partners LLC increased its stake in shares of AstraZeneca by 3.2% in the fourth quarter. Sivia Capital Partners LLC now owns 7,390 shares of the company’s stock valued at $484,000 after buying an additional 226 shares in the last quarter. Finally, Moody National Bank Trust Division raised its holdings in shares of AstraZeneca by 20.0% in the fourth quarter. Moody National Bank Trust Division now owns 4,556 shares of the company’s stock valued at $299,000 after buying an additional 758 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of research analyst reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 1.9 %

AZN opened at $65.73 on Tuesday. The firm has a 50 day simple moving average of $66.00 and a 200 day simple moving average of $74.78. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a market cap of $203.80 billion, a price-to-earnings ratio of 31.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the company posted $0.87 EPS. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.